Browsed by
Category: Press Releases

Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma

Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma

February 07, 2022 01:48 PM Eastern Standard Time

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic acid-based immunotherapy, today announced its first Phase 1 clinical study evaluating ITI-3000 in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer that is typically caused by the Merkel cell polyomavirus (MCPyV). The single-center study will be conducted at the University of Washington School of Medicine and the Fred Hutchinson Cancer Center in Seattle, Washington and will be led by Drs. Paul Nghiem, Song Park and David Koelle. ...  Read more